A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges

In 2018/2019 there were a number of initiatives for collaboration between Member States in the European Economic Area (EEA) and the European Commission published a Proposal for a Regulation on Health Technology Assessment. In view of the perceived benefits from collaboration, the experiences and cha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patricia Vella Bonanno, Vincent Cassar, Brian Godman
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	pharmaceutical policy international collaboration pricing and reimbursement medicines evidence-based management EEA member states Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/089eb896ab9749db8d3065209daf18e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:089eb896ab9749db8d3065209daf18e5
record_format	dspace
spelling	oai:doaj.org-article:089eb896ab9749db8d3065209daf18e52021-11-12T17:49:16ZA Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges1663-981210.3389/fphar.2021.666405https://doaj.org/article/089eb896ab9749db8d3065209daf18e52021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.666405/fullhttps://doaj.org/toc/1663-9812In 2018/2019 there were a number of initiatives for collaboration between Member States in the European Economic Area (EEA) and the European Commission published a Proposal for a Regulation on Health Technology Assessment. In view of the perceived benefits from collaboration, the experiences and challenges of these collaborative initiatives and the possible implications of the proposed legislation, a study of the evidence on attitudes, perceived impacts and the motivational factors towards European Member State collaboration regarding the pricing and reimbursement of medicines was conducted. This study adopted an evidence–based management approach by Barends and Rousseau. The main findings showed that Member States differed in their motivation for collaboration for different pharmaceutical activities. Member States favoured voluntary co-operation for all activities of pricing and reimbursement except for relative effectiveness assessments where Member State authorities had divergent attitudes and prioritised activities related to the sustainability of their healthcare systems and access to medicines. Contrastingly pharmaceutical companies strongly favoured mandatory cooperation for evaluation. Member States motivation for collaboration was highly dependent on the purpose, political will, implementation climate and cultural factors. Currently, with the experiences of ongoing collaborations, following the progress of the discussion at Council, and with a number of inititatives for new pharmaceutical strategy and policy, it is proposed that Member States use their trust, expertise and knowledge of application of evidence-based decision making for pricing and reimbursement of medicines and apply it to decide the future model for Member State collaboration. The applicability of principles of evidence-based management to pharmaceutical policy can be used as a starting point.Patricia Vella BonannoPatricia Vella BonannoVincent CassarBrian GodmanBrian GodmanBrian GodmanFrontiers Media S.A.articlepharmaceutical policyinternational collaborationpricing and reimbursementmedicinesevidence-based managementEEA member statesTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pharmaceutical policy international collaboration pricing and reimbursement medicines evidence-based management EEA member states Therapeutics. Pharmacology RM1-950
spellingShingle	pharmaceutical policy international collaboration pricing and reimbursement medicines evidence-based management EEA member states Therapeutics. Pharmacology RM1-950 Patricia Vella Bonanno Patricia Vella Bonanno Vincent Cassar Brian Godman Brian Godman Brian Godman A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
description	In 2018/2019 there were a number of initiatives for collaboration between Member States in the European Economic Area (EEA) and the European Commission published a Proposal for a Regulation on Health Technology Assessment. In view of the perceived benefits from collaboration, the experiences and challenges of these collaborative initiatives and the possible implications of the proposed legislation, a study of the evidence on attitudes, perceived impacts and the motivational factors towards European Member State collaboration regarding the pricing and reimbursement of medicines was conducted. This study adopted an evidence–based management approach by Barends and Rousseau. The main findings showed that Member States differed in their motivation for collaboration for different pharmaceutical activities. Member States favoured voluntary co-operation for all activities of pricing and reimbursement except for relative effectiveness assessments where Member State authorities had divergent attitudes and prioritised activities related to the sustainability of their healthcare systems and access to medicines. Contrastingly pharmaceutical companies strongly favoured mandatory cooperation for evaluation. Member States motivation for collaboration was highly dependent on the purpose, political will, implementation climate and cultural factors. Currently, with the experiences of ongoing collaborations, following the progress of the discussion at Council, and with a number of inititatives for new pharmaceutical strategy and policy, it is proposed that Member States use their trust, expertise and knowledge of application of evidence-based decision making for pricing and reimbursement of medicines and apply it to decide the future model for Member State collaboration. The applicability of principles of evidence-based management to pharmaceutical policy can be used as a starting point.
format	article
author	Patricia Vella Bonanno Patricia Vella Bonanno Vincent Cassar Brian Godman Brian Godman Brian Godman
author_facet	Patricia Vella Bonanno Patricia Vella Bonanno Vincent Cassar Brian Godman Brian Godman Brian Godman
author_sort	Patricia Vella Bonanno
title	A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
title_short	A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
title_full	A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
title_fullStr	A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
title_full_unstemmed	A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
title_sort	review of the evidence on attitudes, perceived impacts and motivational factors for european member state collaboration for pricing and reimbursement of medicines: time for the eea member states to apply their experience and expertise in evidence-based decision making to their current pharmaceutical policy challenges
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/089eb896ab9749db8d3065209daf18e5
work_keys_str_mv	AT patriciavellabonanno areviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutic AT patriciavellabonanno areviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutic AT vincentcassar areviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutic AT briangodman areviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutic AT briangodman areviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutic AT briangodman areviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutic AT patriciavellabonanno reviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutica AT patriciavellabonanno reviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutica AT vincentcassar reviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutica AT briangodman reviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutica AT briangodman reviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutica AT briangodman reviewoftheevidenceonattitudesperceivedimpactsandmotivationalfactorsforeuropeanmemberstatecollaborationforpricingandreimbursementofmedicinestimefortheeeamemberstatestoapplytheirexperienceandexpertiseinevidencebaseddecisionmakingtotheircurrentpharmaceutica
_version_	1718430296543592448

Ejemplares similares